The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Fin...

Por Tolnay, Edina, Ghimessy, Áron Kristóf, Juhász, Erzsébet, Sztancsik, Zsuzsanna, Losonczy, György, Dombi, Péter, Vennes, Zsuzsanna, Helf, László, Csada, Edit, Sárosi, Veronika
Publicado no Oncol Lett (2019)

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer...

Por von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Publicado no Oncologist (2018)

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Por Quoix, Elisabeth, Sequist, Lecia, Nemunaitis, John, Beck, Thaddeus, Jaskiewicz, Piotr, Oster, Jean-Philippe, Scherpereel, Arnaud, Juhász, Erzsébet, Mark, Zsuzsanna, Alvarez, Rosa, Waqar, Saiama, Potz, Joseph, Vrindavanam, Nandagopal, Melnyk, Anton, Ross, Helen, Limacher, Jean-Marc
Publicado no J Immunother Cancer (2014)